B
B

Biogen


財經新聞

Japan gives priority review status to Alzheimer's drug developed by Eisai, Biogen

UPDATE 1-Japan gives priority review status to Alzheimer's drug developed by Eisai, Biogen Recasts headline, adds background details throughout Jan 29 (Reuters) - Japanese drugmaker Eisai Co Ltd 4523.T and U.S. biotech firm Biogen Inc BIIB.O said in a joint statement that the Japanese Ministry of Health, Labour and Welfare has granted priority review status to their Alzheimer's disease treatment.
B

Japan gives priority review status to Alzheimer's drug developed by Eisai, Biogen

UPDATE 1-Japan gives priority review status to Alzheimer's drug developed by Eisai, Biogen Recasts headline, adds background details throughout Jan 29 (Reuters) - Japanese drugmaker Eisai Co Ltd 4523.T and U.S. biotech firm Biogen Inc BIIB.O said in a joint statement that the Japanese Ministry of Health, Labour and Welfare has granted priority review status to their Alzheimer's disease treatment.
B

Japan grants priority review status to Alzheimer's treatment from Eisai-Biogen

Japan grants priority review status to Alzheimer's treatment from Eisai-Biogen Jan 29 (Reuters) - Japanese drugmaker Eisai Co Ltd 4523.T and Biogen Inc BIIB.O said on Sunday the Japanese Ministry of Health, Labour and Welfare has given priority review for their Alzheimer's disease drug. The drug, lecanemab, which was recently granted accelerated approval in the United States, is an antibody that has been shown to remove sticky deposits of a protein called amyloid beta from the brains of patients
B

Eisai and Biogen Announce Lecanemab Receives Priority Review Status In Japan

BRIEF-BRIEF-Eisai and Biogen Announce Lecanemab Receives Priority Review Status In Japan Jan 29 (Reuters) - Biogen Inc BIIB.O : EISAI CO., LTD. (HEADQUARTERS: TOKYO, CEO: HARUO NAITO, "EISAI") AND BIOGEN INC. (NASDAQ: BIIB, CORPORATE HEADQUARTERS: CAMBRIDGE, MASSACHUSETTS, CEO: CHRISTOPHER A. VIEHBACHER, "BIOGEN") ANNOUNCED TODAY THAT AN APPLICATION FOR MANUFACTURING AND MARKETING APPROVAL FOR LECANEMAB (GENERIC NAME, U.S.
B

EU regulator accepts for review Alzheimer's treatment from Eisai-Biogen

UPDATE 1-EU regulator accepts for review Alzheimer's treatment from Eisai-Biogen Adds background Jan 26 (Reuters) - Japanese drugmaker Eisai Co Ltd 4523.T and Biogen Inc BIIB.O said on Thursday the European Medicines Agency (EMA) had accepted a marketing authorization application for their Alzheimer's disease drug. The drug, lecanemab, which was recently granted accelerated approval in the United States, is an antibody that has been shown to remove sticky deposits of a protein called amyloid bet
B

EU regulator accepts for review Alzheimer's treatment from Eisai-Biogen

UPDATE 1-EU regulator accepts for review Alzheimer's treatment from Eisai-Biogen Adds background Jan 26 (Reuters) - Japanese drugmaker Eisai Co Ltd 4523.T and Biogen Inc BIIB.O said on Thursday the European Medicines Agency (EMA) had accepted a marketing authorization application for their Alzheimer's disease drug. The drug, lecanemab, which was recently granted accelerated approval in the United States, is an antibody that has been shown to remove sticky deposits of a protein called amyloid bet
B

EU regulator accepts Biogen-Eisai's Alzheimer's treatment lecanemab for review

EU regulator accepts Biogen-Eisai's Alzheimer's treatment lecanemab for review Jan 26 (Reuters) - Eisai Co Ltd 4523.T and Biogen Inc BIIB.O said on Thursday the European Medicines Agency (EMA) had accepted a marketing authorization application for their Alzheimer's disease drug for review. The drug, lecanemab, was recently granted accelerated approval in the United States.
B

Lonza to buy back $2.17 bln worth of shares, backs mid-term growth

UPDATE 2-Lonza to buy back $2.17 bln worth of shares, backs mid-term growth Adds background on investments, headwinds By Ludwig Burger and Tristan Chabba Jan 25 (Reuters) - Lonza LONN.S on Wednesday said it will buy back shares worth 2 billion Swiss francs ($2.17 billion), despite an expected drop in annual margins, as the Swiss drug contract manufacturer backed its growth prospects for the near future.
B
L

Lonza full-year earnings edge market expectations

Lonza full-year earnings edge market expectations Jan 25 (Reuters) - Swiss drug contract manufacturer Lonza LONN.S reported full-year core earnings above expectations, as demand from biopharmaceutical companies remained strong throughout the year. The Basel-based firm reported core EBITDA, or earnings before interest, taxes, depreciation, amortisation and special items, of 2.0 billion Swiss francs ($2.17 billion), up 19.8%.
B
L

Eli Lilly Alzheimer's drug setback extends rival Biogen's lead

UPDATE 1-Eli Lilly Alzheimer's drug setback extends rival Biogen's lead Adds Biogen share movement, background, updates Eli Lilly shares Jan 20 (Reuters) - The U.S. health regulator's rejection of accelerated approval for Eli Lilly and Co's LLY.N Alzheimer's disease drug extends the market lead for rivals Eisai and Biogen's treatment by months, analysts said.
B

U.S. STOCKS Netflix, PagerDuty, Proterra

BUZZ-U.S. STOCKS ON THE MOVE-Netflix, PagerDuty, Proterra Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 The S&P 500 and the Nasdaq rose on Friday after Netflix kicked off the earnings season for growth stocks on an upbeat note, while Google parent Alphabet gained on news of job cuts.
A
B
B
B
C
D
G
H
N
S
T
U
T
T
U
U
R

U.S. STOCKS Biogen, Wayfair, Costco

BUZZ-U.S. STOCKS ON THE MOVE-Biogen, Wayfair, Costco Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 Nasdaq futures rose on Friday, after Netflix kicked off the earnings season for the growth sector on a positive note, but worries about a U.S.
A
B
B
C
D
F
G
H
N
S
T
T
U
R

Eli Lilly Alzheimer's drug setback extends rival Biogen's lead - analysts

Eli Lilly Alzheimer's drug setback extends rival Biogen's lead - analysts Jan 20 (Reuters) - The U.S. health regulator's rejection of accelerated approval for Eli Lilly and Co's LLY.N Alzheimer's disease drug extends the market lead for rivals Eisai and Biogen's treatment by months, analysts said. The U.S. Food and Drug Administration (FDA) declined to approve donanemab because Lilly had not submitted data from enough patients who were treated for at least a year, the drugmaker said late Thursda
B

Eli Lilly says U.S. FDA rejects accelerated approval for Alzheimer's drug

UPDATE 3-Eli Lilly says U.S. FDA rejects accelerated approval for Alzheimer's drug Adds neurologist comments, patient advocacy group comment By Deena Beasley Jan 19 (Reuters) - Eli Lilly and Co LLY.N on Thursday said the U.S. Food and Drug Administration had rejected accelerated approval of its experimental Alzheimer's drug because it had not submitted enough trial data from patients who were treated for at least a year.
B

U.S. STOCKS Apple, Surmodics, Domino's

BUZZ-U.S. STOCKS ON THE MOVE-Apple, Surmodics, Domino's Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 U.S. stock indexes were set to open lower on Thursday as recession worries crept into the foreground of the earnings season, while shares of Procter & Gamble fell as it warned of cost pressures.
A
A
A
B
G
H
J
M
T
T
U
E
R

Eisai files for approval of Alzheimer's drug in Japan

(Updates with background) Jan 16 (Reuters) - Japanese drugmaker Eisai Co Ltd 4523.T said on Monday it had submitted a marketing authorisation application in Japan for its Alzheimer's drug lecanemab, which was recently granted accelerated approval in the United States. The drug, developed in partnership with Biogen Inc BIIB.O , is an antibody that has been shown to remove sticky deposits of a protein called amyloid beta from the brains of those in the early stages of the mind-wasting disease.
B

Wall St rallies as jobs, services data calm rate hike worries

(For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news window) * U.S. December payrolls up 223,000 vs est 200,000 * Dec. non-manufacturing PMI 49.6 vs November's 56.5 read * Biogen closes higher as FDA approves Alzheimer's drug * Indexes up: Dow 2.13%, S&P 2.28%, Nasdaq 2.56% By Sinéad Carew and Ankika Biswas Jan 6 (Reuters) - Wall Street's main indexes all gained more than 2% on Friday after December payrolls expanded more than expected even as wag
B
B
C
P
U
U

Wall Street ends sharply higher after Powell comments

(For a Reuters live blog on U.S., UK and European stock markets, click or type LIVE/ in a news window) * Tesla rises as sales in China nearly double in November - data * U.S. private payrolls growth slows in November - ADP * Powell says Fed could scale back rate hikes in December * Indexes end: S&P 500 +3.09%, Nasdaq +4.41%, Dow +2.18% (Updates with detail on S&P 500 moving average, graphics) By Noel Randewich and Shreyashi Sanyal Nov 30 (Reuters) - Wall Street ended sharply higher on Wednesday
A
B
M
N
T
U
U

Wall Street ends sharply higher after Powell comments

(For a Reuters live blog on U.S., UK and European stock markets, click or type LIVE/ in a news window) * Tesla rises as sales in China nearly double in November - data * U.S. private payrolls growth slows in November - ADP * Powell says Fed could scale back rate hikes in December * Indexes end: S&P 500 +3.09%, Nasdaq +4.41%, Dow +2.18% (Updates with details following close of trading session) By Noel Randewich and Shreyashi Sanyal Nov 30 (Reuters) - Wall Street ended sharply higher on Wednesday
A
B
M
N
T
U
U

Wall Street ends sharply higher after Powell comments

(For a Reuters live blog on U.S., UK and European stock markets, click or type LIVE/ in a news window) * Tesla rises as sales in China nearly double in November - data * U.S. private payrolls growth slows in November - ADP * Powell says Fed could scale back rate hikes in December (Updates with details at close of trading session) By Noel Randewich and Shreyashi Sanyal Nov 30 (Reuters) - Wall Street ended sharply higher on Wednesday after Federal Reserve Chair Jerome Powell said the central bank
A
B
N
T
U
U



細節

熱門資產

免責聲明: XM Group提供線上交易平台的登入和執行服務,允許個人查看和/或使用網站所提供的內容,但不進行任何更改或擴展其服務和訪問權限,並受以下條款與條例約束:(i)條款與條例;(ii)風險提示;(iii)完全免責聲明。網站內部所提供的所有資訊,僅限於一般資訊用途。請注意,我們所有的線上交易平台內容並不構成,也不被視為進入金融市場交易的邀約或邀請 。金融市場交易會對您的投資帶來重大風險。

所有缐上交易平台所發佈的資料,僅適用於教育/資訊類用途,不包含也不應被視爲適用於金融、投資稅或交易相關諮詢和建議,或是交易價格紀錄,或是任何金融商品或非應邀途徑的金融相關優惠的交易邀約或邀請。

本網站的所有XM和第三方所提供的内容,包括意見、新聞、研究、分析、價格其他資訊和第三方網站鏈接,皆爲‘按原狀’,並作爲一般市場評論所提供,而非投資建議。請理解和接受,所有被歸類為投資研究範圍的相關内容,並非爲了促進投資研究獨立性,而根據法律要求所編寫,而是被視爲符合營銷傳播相關法律與法規所編寫的内容。請確保您已詳讀並完全理解我們的非獨立投資研究提示和風險提示資訊,相關詳情請點擊 這裡查看。

我們運用 cookies 提供您最佳之網頁使用經驗。更改您的cookie 設定跟詳情。

風險提示:您的資金存在風險。槓桿商品並不適合所有客戶。請詳細閱讀我們的風險聲明